Aztreonam (Cayston): Uses, Dosage, and Side Effects

Aztreonam is a bactericidal antibiotic used primarily against susceptible gram-negative aerobic bacteria. In respiratory care, its most important application is the inhaled formulation, known as Cayston, which is used in patients with cystic fibrosis who have pulmonary infection or colonization with Pseudomonas aeruginosa.

Delivering aztreonam by aerosol allows the medication to reach the respiratory tract directly, where chronic infection occurs.

Proper therapy requires correct patient selection, dosing, nebulizer use, treatment sequencing, pulmonary assessment, and monitoring for bronchospasm, allergic reactions, and other adverse effects.

What Is Aztreonam?

Aztreonam is an antibacterial medication that belongs to the monobactam class of antibiotics. It is considered a synthetic bactericidal drug because it kills susceptible bacteria by disrupting their ability to construct a functional cell wall.

Aztreonam was originally developed as a systemic antibiotic. The intravenous formulation was approved in 1986 for the treatment of susceptible bacterial infections. An inhaled formulation was later developed to provide direct antimicrobial therapy within the respiratory tract.

The inhaled formulation is marketed under the brand name Cayston. It was developed primarily for patients with cystic fibrosis who have chronic pulmonary infection involving Pseudomonas aeruginosa.

In respiratory care, the important distinction is that aztreonam is not a bronchodilator, corticosteroid, mucolytic, or airway-clearance medication. It is an antibiotic, meaning its primary function is to act against susceptible bacteria.

Aztreonam Drug Classification

Aztreonam is classified as a monobactam antibiotic. Monobactams are structurally related to other beta-lactam antimicrobial agents because they interfere with bacterial cell-wall synthesis. However, aztreonam has a distinct chemical structure compared with many other beta-lactam antibiotics.

The drug is primarily active against gram-negative aerobic bacteria. One of the most clinically important organisms within this spectrum is Pseudomonas aeruginosa.

Aztreonam is considered bactericidal, meaning that it causes bacterial death rather than simply slowing bacterial growth. This characteristic is related directly to its mechanism of action against the bacterial cell wall.

Mechanism of Action

Aztreonam works by interfering with the formation of the bacterial cell wall. The drug binds to specific structures known as penicillin-binding proteins. These proteins participate in the synthesis and maintenance of the bacterial cell wall, which provides structural support and allows the organism to survive.

When aztreonam binds to penicillin-binding proteins, normal cell-wall construction is disrupted. The bacteria become unable to maintain an intact protective wall, eventually resulting in bacterial destruction and death.

The basic mechanism can be summarized as follows:

• Aztreonam reaches susceptible bacteria.
• The drug binds to penicillin-binding proteins.
• Bacterial cell-wall synthesis is inhibited.
• The bacterial cell wall loses structural integrity.
• The organism dies.

Note: This bactericidal activity makes aztreonam useful against susceptible gram-negative organisms, including Pseudomonas aeruginosa.

Aztreonam and Cystic Fibrosis

The most important respiratory indication for inhaled aztreonam is related to cystic fibrosis, commonly abbreviated CF. Cystic fibrosis is an inherited disease involving abnormal exocrine gland function. Although several organ systems may be affected, respiratory complications are among the most significant.

Patients with cystic fibrosis produce abnormally thick respiratory secretions. These secretions are difficult to clear from the airways and can contribute to chronic obstruction, impaired ventilation, inflammation, and recurrent infection.

As respiratory disease progresses, patients may develop:

• Chronic productive coughing
• Wheezing
• Rhonchi
• Crackles
• Airway obstruction
• Recurrent respiratory infections
• Bronchiectasis
• Air trapping
• Reduced pulmonary function
• Progressive decline in FEV₁

Note: Because retained mucus provides an environment in which microorganisms can persist, chronic bacterial infection becomes an important part of cystic fibrosis lung disease.

Pseudomonas aeruginosa Infection

Pseudomonas aeruginosa is one of the most important respiratory pathogens associated with cystic fibrosis.

It is a gram-negative aerobic bacterium capable of establishing persistent infection within abnormal airways. Chronic Pseudomonas infection can contribute to increased respiratory symptoms, repeated pulmonary exacerbations, airway inflammation, and progressive loss of pulmonary function.

Once persistent colonization or infection develops, eradication may be difficult. Long-term treatment strategies may therefore focus on reducing bacterial burden, improving respiratory symptoms, and limiting the effects of chronic infection.

Inhaled aztreonam is specifically intended to help control pulmonary infection associated with Pseudomonas aeruginosa in appropriate patients with cystic fibrosis.

Why Aztreonam Is Given by Inhalation

Antibiotics can be delivered systemically, but direct aerosol administration offers several potential advantages for chronic respiratory infection.

When aztreonam is inhaled, the medication can be deposited directly within the respiratory tract. This allows a high concentration of antibiotic to reach the area where the bacterial infection is located.

The major advantages of inhaled antimicrobial therapy include:

• Direct delivery to the respiratory tract
• High local drug concentrations
• Reduced dependence on systemic circulation for pulmonary drug delivery
• Potential reduction in unnecessary systemic exposure
• Targeted treatment of chronic airway infection

Note: This approach is particularly useful in diseases such as cystic fibrosis, where organisms can persist within thick respiratory secretions and structurally abnormal airways. The goal is not merely to administer an antibiotic by a different route. The aerosol route is selected because it can place the antimicrobial medication close to the site of infection.

What Is Cayston?

Cayston is the inhaled formulation of aztreonam used in respiratory care. It contains aztreonam formulated specifically for aerosol administration and should not be treated as interchangeable with systemic aztreonam preparations. Cayston is supplied in single-use vials and must be reconstituted before administration.

Each vial contains approximately:

• 75 mg of lyophilized aztreonam
• A nominal vial size of 2 mL
• Medication intended for reconstitution with the supplied diluent
• 1 mL of 0.17% sodium chloride as the diluent

Note: Once reconstituted, the solution is administered by inhalation using the designated nebulizer system. Following preparation instructions is important because aerosol delivery depends on the physical properties of the medication and the device used to produce the aerosol.

Aztreonam Dosage

The standard inhaled dose of Cayston is:

75 mg three times daily.

The medication is given over a 28-day treatment period. After completing 28 consecutive days of therapy, the patient stops Cayston for the next 28 days.

The schedule can therefore be remembered as:

28 days on treatment, followed by 28 days off treatment.

This cycle may be repeated according to the patient’s prescribed cystic fibrosis treatment plan. The major dosing information for examination purposes is:

• Dose: 75 mg
• Frequency: Three times daily
• Treatment period: 28 days
• Off period: 28 days

Note: This cyclic regimen is commonly associated with chronic inhaled antibiotic management in cystic fibrosis.

Why Aztreonam Is Given in Cycles

Patients with chronic Pseudomonas aeruginosa infection may require repeated antimicrobial treatment over long periods. However, continuous antibiotic exposure is not always desirable. Cyclic administration provides defined periods of active treatment followed by periods without the medication.

The 28-days-on and 28-days-off schedule is therefore an important part of inhaled aztreonam therapy. Some patients may also receive alternating inhaled antibiotics as part of a larger treatment plan. For example, an inhaled aztreonam cycle may be incorporated with treatment involving inhaled tobramycin.

The exact regimen depends on the individual patient, microbiological findings, physician orders, and long-term cystic fibrosis management strategy.

Altera Nebulizer System

Cayston should be administered using the Altera Nebulizer System. This is a critical point because nebulized medications should not automatically be placed in any available nebulizer.

Different aerosol generators can vary in:

• Aerosol output
• Particle size
• Residual medication volume
• Treatment time
• Medication deposition
• Delivery efficiency

Note: A drug evaluated with one aerosol-delivery system may not produce the same pulmonary dose when administered through a different device. The Altera system is specifically associated with Cayston administration and helps provide the intended aerosol characteristics.

Vibrating-Mesh Nebulization

The Altera is an electronic vibrating-mesh nebulizer. Vibrating-mesh nebulizers produce aerosol by moving liquid medication through extremely small openings in a mesh or membrane. This creates fine droplets that can be inhaled into the respiratory tract.

Potential benefits of vibrating-mesh nebulizers include:

• Efficient aerosol generation
• Low residual medication volume
• Relatively rapid treatment
• Quiet operation
• Portable design
• No need for an external compressed-gas source
• Limited heating of the medication

Note: These characteristics make vibrating-mesh nebulizers useful for certain specialized medications, including inhaled aztreonam. Proper assembly, cleaning, maintenance, and medication preparation are still essential. A malfunctioning or contaminated device can interfere with therapy.

Do Not Mix Cayston With Other Nebulized Medications

Cayston should be administered by itself through the designated nebulizer system. The drug should not simply be mixed with bronchodilators, mucolytics, or other inhaled medications in the same nebulizer chamber unless specific compatibility and administration instructions support doing so.

Mixing medications can potentially alter:

• Drug stability
• Aerosol characteristics
• Medication concentration
• Particle formation
• Delivered dose
• Treatment effectiveness

Note: For this reason, respiratory medications given during the same treatment session should generally be administered separately and in the proper sequence.

Bronchodilator Pretreatment

One of the most important respiratory-care considerations associated with Cayston is bronchodilator pretreatment. A bronchodilator should be given before inhaled aztreonam.

This recommendation exists because aerosolized antibiotics can irritate the respiratory tract and trigger bronchospasm. A fast-onset beta-adrenergic bronchodilator may be administered before Cayston to improve airway caliber and reduce the likelihood or severity of treatment-related airway narrowing.

This creates a high-yield medication sequence:

Bronchodilator first, Cayston afterward.

Bronchodilator pretreatment is especially important in patients who already have significant airflow obstruction.

Bronchospasm

Bronchospasm is one of the most important respiratory adverse effects associated with inhaled aztreonam. Bronchospasm occurs when bronchial smooth muscle contracts, causing narrowing of the airways. This can increase airway resistance and make breathing more difficult.

Possible clinical findings include:

• Wheezing
• Chest tightness
• Increased work of breathing
• Decreased airflow
• Reduced peak expiratory flow
• Reduced FEV₁
• Dyspnea

Note: Because patients with cystic fibrosis may already have substantial airway obstruction, further narrowing caused by an inhaled medication can be clinically significant. The patient should therefore be assessed before and after treatment, especially when therapy is first initiated.

Baseline Pulmonary Function Assessment

Pulmonary function should be evaluated before starting inhaled aztreonam. FEV₁, or forced expiratory volume in the first second, is particularly useful because it provides an objective measurement of expiratory airflow.

Establishing a baseline allows the clinician to determine whether lung function decreases following administration.

Relevant respiratory assessment may include:

• FEV₁
• Peak expiratory flow
• Breath sounds
• Respiratory rate
• Work of breathing
• Oxygen saturation
• Patient-reported dyspnea
• Presence of wheezing or chest tightness

Note: A meaningful decline after treatment may indicate medication-associated bronchospasm.

Patient Populations and Pulmonary Function

Inhaled aztreonam was studied in a relatively specific cystic fibrosis population. The information provided describes patients with an FEV₁ greater than 25% of predicted but less than 75% of predicted.

This range is important because evidence from one population cannot automatically be assumed to apply equally to patients with substantially more severe or substantially milder pulmonary impairment. The patient’s overall respiratory status should therefore be considered when evaluating therapy.

Age Considerations

Cayston is associated with use in patients with cystic fibrosis who are 7 years of age or older. Patients younger than 7 years were not part of the population for which the described inhaled indication was established.

Age should therefore be considered when reviewing an order for inhaled aztreonam. For examination questions, the distinction between Cayston and other inhaled antibiotics may be important because different medications can have different age recommendations.

Burkholderia cepacia Considerations

Cayston is specifically associated with Pseudomonas aeruginosa infection and should not automatically be used for every organism found in a patient with cystic fibrosis. In particular, the information provided identifies Burkholderia cepacia as a population in which inhaled aztreonam was not indicated or adequately studied.

This reinforces the importance of identifying the infecting organism before selecting antimicrobial therapy. Cystic fibrosis patients may develop pulmonary infection or colonization involving multiple organisms, including:

• Pseudomonas aeruginosa
• Staphylococcus aureus
• Haemophilus influenzae
• Burkholderia cepacia

Note: The correct antibiotic depends on the organism and its susceptibility.

Culture and Susceptibility Testing

Antibiotic selection should be guided by microbiological information whenever appropriate. Respiratory cultures can identify the organism present in airway secretions, while susceptibility testing can help determine whether that organism remains sensitive to a specific antimicrobial agent.

This is particularly important in chronic cystic fibrosis infection because patients may receive repeated antibiotic courses over long periods. Repeated antimicrobial exposure can create selective pressure that favors resistant organisms.

Therefore, knowing that aztreonam generally has antipseudomonal activity does not mean that every Pseudomonas aeruginosa isolate will necessarily remain susceptible.

Antibiotic Resistance

Antimicrobial resistance is an important consideration when using aztreonam. Cayston should not be administered simply because a patient has cystic fibrosis. The patient should have an appropriate indication involving Pseudomonas aeruginosa pulmonary infection or colonization.

Unnecessary antibiotic exposure can contribute to the selection of resistant bacteria. Appropriate antimicrobial stewardship includes:

• Confirming that an antibiotic is indicated
• Considering respiratory culture results
• Reviewing susceptibility patterns
• Using the prescribed dose
• Following the recommended treatment schedule
• Avoiding unnecessary antimicrobial exposure
• Monitoring the patient’s clinical response

Note: The goal is to provide effective therapy while minimizing avoidable selection pressure for resistance.

Sequencing Aztreonam With Other Cystic Fibrosis Therapies

Patients with cystic fibrosis often receive several respiratory treatments during the same therapy session. The order in which these treatments are given can affect their effectiveness.

A commonly described sequence is:

1. Bronchodilator
2. Mucolytic or mucus-controlling therapy
3. Airway-clearance or bronchial hygiene therapy
4. Other indicated inhaled medications
5. Inhaled antibiotic such as Cayston

Note: Giving the bronchodilator first helps open the airways. Mucolytic or secretion-mobilizing therapy can then help decrease mucus viscosity or improve secretion clearance. Airway-clearance therapy removes secretions from the respiratory tract. The antibiotic is then administered after the airways have been opened and cleared.

Why Cayston Is Given After Airway Clearance

Giving aztreonam near the end of the treatment sequence has practical advantages. If the antibiotic were administered immediately before aggressive airway-clearance therapy, some of the deposited medication could potentially be removed along with respiratory secretions.

Performing airway clearance first helps create a more open pathway for subsequent aerosol deposition. The general strategy is therefore:

Open the airways, mobilize secretions, clear the airways, then administer the antibiotic.

This sequence integrates antimicrobial treatment with the overall physiologic goals of cystic fibrosis respiratory care.

Mucolytics and Secretion-Mobilizing Therapy

Several mucus-directed treatments may be used in cystic fibrosis.

Examples include:

• Dornase alfa
• Hypertonic saline
• N-acetylcysteine when prescribed
• Other mucus-management strategies

These therapies may be administered before Cayston when they are part of the patient’s prescribed regimen. The purpose is to reduce secretion obstruction and facilitate airway clearance before antibiotic deposition.

Note: Airway-clearance techniques may then be performed to physically mobilize and remove mucus.

Airway-Clearance Therapy

Airway-clearance therapy is a major component of cystic fibrosis management because thick secretions are difficult to remove naturally.

Methods may include:

• Directed coughing
• Huff coughing
• Chest physiotherapy
• Positive expiratory pressure therapy
• Oscillatory devices
• High-frequency chest-wall oscillation
• Other prescribed bronchial hygiene techniques

Note: The exact method varies according to the patient’s age, disease severity, preferences, and treatment plan. When Cayston is included in the regimen, airway clearance is generally performed before the inhaled antibiotic.

Monitoring During Aztreonam Administration

Patients should be observed during inhaled aztreonam treatment, particularly when therapy is being initiated. Monitoring should focus on both therapeutic tolerance and adverse respiratory responses.

Assessment may include:

• Breath sounds
• Respiratory rate
• Heart rate
• Oxygen saturation
• Work of breathing
• Cough
• Wheezing
• Chest discomfort
• Patient-reported symptoms

Note: The first treatment deserves particular attention because the clinician does not yet know how the patient will tolerate the aerosol. If significant difficulty breathing develops, treatment should be stopped and the appropriate healthcare provider notified.

Allergic Reactions

Aztreonam can cause hypersensitivity reactions. Severe allergic reactions have been reported with systemic aztreonam, so patients receiving inhaled therapy should also be observed for signs of hypersensitivity.

Potential warning signs may include:

• Sudden respiratory deterioration
• Wheezing beyond the expected response
• Rash
• Swelling
• Difficulty breathing
• Other signs of systemic allergic reaction

Note: If a significant allergic reaction occurs, the aerosol treatment should be discontinued and appropriate medical evaluation initiated. The patient should not simply be encouraged to finish the treatment despite signs of a serious reaction.

Other Adverse Effects

In addition to bronchospasm and allergic reactions, inhaled aztreonam may be associated with several other adverse effects.

Reported effects include:

• Cough
• Nasal congestion
• Throat discomfort
• Fever
• Chest discomfort
• Abdominal discomfort
• Airway irritation

Note: Some local airway symptoms can occur because aerosolized medication comes into direct contact with respiratory tissues. The presence, severity, and progression of symptoms should be assessed rather than assuming every complaint is harmless.

Environmental Exposure During Aerosolized Antibiotic Therapy

Aerosolized antibiotics can potentially escape into the surrounding environment during administration. This may expose healthcare workers, family members, or others nearby to small amounts of medication.

General infection-control and aerosol-safety principles therefore remain relevant. Proper use of the designated nebulizer, appropriate ventilation, correct equipment setup, and adherence to manufacturer recommendations can help reduce unnecessary environmental exposure.

Note: Consideration may also be given to allergies among people who may be repeatedly exposed to medication aerosol.

Storage of Cayston

Cayston treatment kits should generally be stored under refrigeration. When needed for active treatment, the medication may be kept at room temperature for a limited period of up to approximately 28 days.

Storage recommendations are important because the medication must remain stable and suitable for administration throughout the treatment cycle.

Patients receiving therapy at home should understand:

• Where to store the medication
• How long it may remain unrefrigerated
• How to prepare each dose
• When the reconstituted medication should be used
• How to clean and maintain the nebulizer

Note: Home education is particularly important because the medication is often administered repeatedly outside the hospital setting.

Aztreonam Compared With Tobramycin

Aztreonam and inhaled tobramycin are both associated with treatment of chronic Pseudomonas aeruginosa pulmonary infection in cystic fibrosis. However, the two medications should not be confused.

Aztreonam as Cayston is commonly remembered as:

• 75 mg
• Three times daily
• 28 days on, 28 days off
• Altera Nebulizer System
• Associated with patients 7 years of age and older

Note: Inhaled tobramycin uses different doses, frequencies, formulations, and delivery devices. The shared clinical purpose does not mean that the medications are interchangeable from an administration standpoint.

Role of the Respiratory Therapist

Respiratory therapists may have several responsibilities when caring for a patient receiving inhaled aztreonam.

These can include:

• Confirming the prescribed medication and dose
• Reviewing the indication
• Assessing baseline respiratory status
• Administering the bronchodilator first
• Coordinating mucolytic and airway-clearance therapy
• Preparing the nebulizer system
• Ensuring correct Cayston reconstitution
• Administering the medication through the Altera system
• Monitoring breath sounds and vital signs
• Watching for bronchospasm
• Recognizing possible allergic reactions
• Evaluating treatment tolerance
• Educating the patient about equipment and technique

Note: The respiratory therapist should understand that successful therapy depends on more than placing medication into a nebulizer. Device selection, treatment sequencing, assessment, and patient education all influence the quality of aerosol therapy.

Evaluating Treatment Effectiveness

The effectiveness of inhaled aztreonam should be evaluated within the broader context of cystic fibrosis management.

Possible indicators include:

• Changes in respiratory symptoms
• Changes in cough or sputum production
• Breath-sound findings
• Oxygen saturation
• Frequency of pulmonary exacerbations
• Pulmonary function measurements
• FEV₁ trends
• Respiratory culture findings
• Overall treatment tolerance

Note: A single nebulizer treatment is not expected to reverse chronic cystic fibrosis lung disease. Aztreonam is part of a longer-term strategy intended to control chronic bacterial burden and improve pulmonary symptoms.

Importance of Nebulizer Cleaning

Repeated inhaled therapy creates a risk of device contamination if the nebulizer is not cleaned properly. This is especially important in cystic fibrosis because patients are already vulnerable to chronic respiratory infection.

The patient and family should receive instructions regarding appropriate cleaning, disinfection, drying, assembly, and storage of reusable nebulizer components.

Failure to maintain respiratory equipment correctly can potentially introduce microorganisms into the airway or interfere with device performance. Instructions should follow the manufacturer’s recommendations for the Altera system.

Infection Control in Cystic Fibrosis

Infection control is an important part of cystic fibrosis respiratory management. Patients with cystic fibrosis may carry clinically significant organisms that can potentially be transmitted to other patients with CF.

Appropriate precautions may include:

• Hand hygiene
• Proper disposal or containment of respiratory secretions
• Correct cleaning of nebulizer equipment
• Avoidance of unnecessary equipment sharing
• Following recommended isolation or transmission precautions
• Limiting close contact between patients with cystic fibrosis when indicated

Note: These principles are relevant during chronic inhaled antibiotic treatment because repeated handling of nebulizer equipment provides opportunities for contamination if proper technique is not followed.

Patient Education

Patient education can improve the safety and consistency of inhaled aztreonam therapy. Patients should understand why the medication is being prescribed and why the treatment schedule must be followed.

Important education points include:

• Cayston is an antibiotic for pulmonary Pseudomonas aeruginosa infection.
• The usual dose is 75 mg three times daily.
• Treatment is given for 28 days followed by 28 days off.
• The medication must be prepared correctly.
• The Altera Nebulizer System should be used.
• A bronchodilator should be taken before Cayston as prescribed.
• Airway-clearance therapies should generally occur before the antibiotic.
• The medication should not be mixed indiscriminately with other nebulized drugs.
• Worsening breathing should be reported.
• Signs of an allergic reaction require prompt attention.
• Nebulizer equipment must be cleaned appropriately.
• Storage instructions should be followed.

Note: The patient should also understand the importance of completing therapy according to the prescribed schedule rather than changing the regimen without medical guidance.

High-Yield Aztreonam Facts

Several facts are particularly important for students and respiratory-care professionals to remember:

• Drug: Aztreonam
• Inhaled brand: Cayston
• Drug class: Monobactam antibiotic
• Action: Bactericidal
• Primary respiratory target: Pseudomonas aeruginosa
• Primary respiratory population: Patients with cystic fibrosis
• Dose: 75 mg
• Frequency: Three times daily
• Treatment cycle: 28 days on, 28 days off
• Delivery system: Altera Nebulizer System
• Mechanism: Binds penicillin-binding proteins and inhibits bacterial cell-wall synthesis
• Major respiratory adverse effect: Bronchospasm with possible decline in FEV₁
• Pretreatment: Bronchodilator before Cayston
• Typical therapy sequence: Bronchodilator, mucus-directed therapy, airway clearance, then inhaled antibiotic
• Major safety concern: Bronchospasm and possible hypersensitivity reaction
• Antimicrobial stewardship: Use when appropriate Pseudomonas aeruginosa infection or colonization is present

Aztreonam Practice Questions

1. What class of antibiotic does aztreonam belong to?
Aztreonam belongs to the monobactam class of antibiotics.

2. What is the inhaled brand name of aztreonam?
The inhaled form of aztreonam is marketed as Cayston.

3. What type of bacterial activity does aztreonam have?
Aztreonam is bactericidal, meaning it kills susceptible bacteria rather than simply inhibiting their growth.

4. Which group of bacteria is primarily targeted by aztreonam?
Aztreonam is primarily active against susceptible gram-negative aerobic bacteria.

5. Which respiratory pathogen is the primary target of inhaled aztreonam in patients with cystic fibrosis?
The primary target is Pseudomonas aeruginosa.

6. What is the primary respiratory indication for inhaled aztreonam?
Inhaled aztreonam is used to improve pulmonary symptoms in patients with cystic fibrosis who have pulmonary infection or colonization with Pseudomonas aeruginosa.

7. How does aztreonam interfere with bacterial survival?
Aztreonam binds to penicillin-binding proteins and inhibits bacterial cell-wall synthesis, eventually causing bacterial cell death.

8. Why is aerosolized aztreonam useful in treating pulmonary infections?
Aerosolized administration delivers a high concentration of the antibiotic directly to the respiratory tract where the infection is located.

9. What is the recommended inhaled dose of Cayston?
The recommended inhaled dose is 75 mg.

10. How often is Cayston typically administered?
Cayston is typically administered three times per day.

11. What treatment cycle is commonly used for inhaled aztreonam?
Cayston is administered for 28 days followed by 28 days without the medication.

12. Which nebulizer system should be used to administer Cayston?
Cayston should be administered using the Altera Nebulizer System.

13. Why should Cayston not automatically be administered through any available nebulizer?
Different nebulizers can produce different aerosol outputs, particle sizes, residual volumes, and pulmonary doses, so Cayston should be administered through its designated delivery system.

14. What type of nebulizer technology is used by the Altera system?
The Altera system uses vibrating-mesh nebulizer technology.

15. What medication should generally be given before each dose of inhaled aztreonam?
A fast-onset bronchodilator should be administered before Cayston.

16. Why is bronchodilator pretreatment recommended before Cayston?
Bronchodilator pretreatment helps reduce the risk or severity of bronchospasm caused by inhaled aztreonam.

17. What major respiratory adverse effect should be monitored during aztreonam inhalation?
Bronchospasm is a major respiratory adverse effect that should be monitored.

18. What pulmonary function measurement may decrease if Cayston causes bronchospasm?
FEV₁ may decrease if bronchospasm occurs following inhaled aztreonam administration.

19. Why should baseline pulmonary function be assessed before starting Cayston?
Baseline pulmonary function provides a reference for identifying treatment-related decreases in airflow or development of bronchospasm.

20. What should occur before Cayston when a patient is also receiving prescribed mucolytic therapy?
The mucolytic therapy should generally be administered before Cayston.

21. When should airway-clearance therapy be performed in relation to inhaled aztreonam?
Airway-clearance or bronchial hygiene therapy should generally be performed before administering Cayston.

22. What is a typical sequence of respiratory treatments when Cayston is prescribed with other cystic fibrosis therapies?
A typical sequence is bronchodilator, mucus-directed therapy, airway clearance, and then inhaled aztreonam.

23. What should be done if a patient develops significant difficulty breathing during a Cayston treatment?
The treatment should be stopped and the appropriate healthcare provider should be notified.

24. Why should inhaled aztreonam not be routinely given to every patient with cystic fibrosis?
Its use should be directed toward patients with an appropriate Pseudomonas aeruginosa infection or colonization because unnecessary antibiotic exposure can contribute to antimicrobial resistance.

25. What organism-specific limitation is associated with the use of inhaled aztreonam in the information provided?
Inhaled aztreonam was not indicated or adequately studied for cystic fibrosis patients with Burkholderia cepacia.

26. In what year was systemic aztreonam originally approved?
Systemic aztreonam was originally approved in 1986.

27. In what year was the inhaled formulation of aztreonam approved?
The inhaled formulation, Cayston, was approved in 2010.

28. What is contained in each single-use vial of Cayston before reconstitution?
Each vial contains 75 mg of lyophilized aztreonam.

29. How much diluent is used to reconstitute a vial of Cayston?
Each vial is reconstituted with 1 mL of the supplied sterile diluent.

30. What concentration of sodium chloride is used as the Cayston diluent?
The supplied diluent contains 0.17% sodium chloride.

31. Why is correct reconstitution important when preparing inhaled aztreonam?
Correct reconstitution helps ensure that the medication has the intended concentration and physical characteristics for proper aerosol delivery.

32. Should Cayston be mixed with other medications in the same nebulizer chamber?
No. Cayston should be administered by itself through the designated nebulizer system.

33. Why can the viscosity of an antibiotic solution matter during aerosol therapy?
Viscosity can affect nebulizer performance, aerosol production, particle characteristics, and the amount of medication delivered to the lungs.

34. What is one potential advantage of a vibrating-mesh nebulizer compared with a traditional jet nebulizer?
A vibrating-mesh nebulizer can provide efficient aerosol generation without requiring an external compressed-gas source.

35. Why is low residual medication volume desirable in a nebulizer?
A low residual volume reduces the amount of medication left behind in the device and can improve delivery efficiency.

36. What age group was inhaled aztreonam described as being indicated for?
It was described for patients with cystic fibrosis who are 7 years of age or older.

37. What FEV₁ range was described for the population in which inhaled aztreonam was studied?
It was studied in patients with an FEV₁ greater than 25% but less than 75% of predicted.

38. Why is the studied FEV₁ range clinically important?
It identifies the pulmonary-function range in which the evidence for the described therapy was established and cautions against assuming identical results outside that range.

39. Besides FEV₁, what bedside measurement may help detect worsening airflow after an inhaled antibiotic treatment?
Peak expiratory flow can help identify changes in airway caliber after treatment.

40. What should the respiratory therapist listen for during auscultation after Cayston administration?
The therapist should assess for new or worsening wheezing and other changes that could suggest bronchospasm or airway irritation.

41. What common respiratory symptom may occur because aerosolized aztreonam irritates the airways?
Cough may occur as a result of airway irritation.

42. Name one nonrespiratory adverse effect associated with inhaled aztreonam.
Abdominal pain is one reported nonrespiratory adverse effect.

43. Why should patients be observed carefully when first receiving inhaled aztreonam?
Initial observation helps identify bronchospasm, difficulty breathing, or a possible hypersensitivity reaction.

44. What should happen if signs of a significant allergic reaction develop during Cayston administration?
The treatment should be stopped immediately and the healthcare team should be notified.

45. Why is culture testing useful before or during chronic inhaled antibiotic therapy?
Culture testing helps identify the organism present in respiratory secretions and supports organism-directed antimicrobial treatment.

46. What is the purpose of susceptibility testing in a patient receiving repeated antibiotics?
Susceptibility testing helps determine whether the isolated bacteria remain sensitive or have developed resistance to specific antimicrobial agents.

47. Why does the usual activity of aztreonam against Pseudomonas aeruginosa not guarantee that every isolate will respond?
Individual bacterial isolates may develop resistance, so susceptibility can vary from patient to patient.

48. How may inhaled aztreonam be incorporated into a broader chronic antibiotic strategy?
It may be used in alternating cycles with another inhaled antibiotic such as tobramycin.

49. How should Cayston normally be stored before use?
Cayston treatment kits should generally be stored under refrigeration.

50. How long may Cayston generally be kept at room temperature during the treatment period?
It may generally be kept at room temperature for up to 28 days.

51. Why is aztreonam considered a targeted respiratory antibiotic rather than a general aerosol medication?
It is intended specifically for susceptible bacterial infection, especially Pseudomonas aeruginosa pulmonary infection in patients with cystic fibrosis.

52. What structural component of bacteria is ultimately disrupted by aztreonam therapy?
The bacterial cell wall is disrupted because aztreonam interferes with its synthesis.

53. Why is an intact bacterial cell wall important for bacterial survival?
The cell wall provides structural support and helps maintain the integrity of the bacterial cell.

54. What does the term bactericidal mean when describing aztreonam?
Bactericidal means the medication kills susceptible bacteria.

55. Why may inhaled antibiotic therapy reduce systemic drug exposure compared with intravenous therapy?
The medication is delivered directly to the respiratory tract rather than relying primarily on systemic circulation to reach the lungs.

56. Why are chronic airway secretions important in the development of infection in cystic fibrosis?
Thick retained secretions impair airway clearance and create an environment that favors persistent bacterial growth.

57. What pulmonary complication of cystic fibrosis can develop as a result of chronic infection and airway damage?
Bronchiectasis can develop as chronic infection and airway injury progress.

58. What general pattern may be seen on pulmonary function testing in cystic fibrosis?
An obstructive pattern with reduced FEV₁ and a reduced FEV₁/FVC ratio may be present.

59. Why should an inhaled antibiotic generally be given after airway-clearance therapy?
Giving it afterward may improve drug deposition and reduce the chance that deposited medication will be removed during subsequent secretion clearance.

60. What is the purpose of administering a bronchodilator first in a multi-treatment cystic fibrosis regimen?
The bronchodilator improves airway caliber and helps prepare the lungs for subsequent inhaled therapies.

61. What is the purpose of administering mucus-directed therapy before airway clearance?
It helps loosen, thin, or mobilize secretions so they can be removed more effectively.

62. Why is patient breathing pattern important during aerosol therapy?
Breathing pattern can influence how much aerosol reaches the lower respiratory tract and where particles deposit.

63. Why is aerosol particle size important when administering inhaled aztreonam?
Particles must be appropriately sized to travel into the lower respiratory tract and deposit in the intended airways.

64. What problem can occur if most aerosol particles deposit in the mouth or upper airway?
Less medication reaches the lower respiratory tract, reducing the intended pulmonary dose.

65. Why is prompt use of reconstituted Cayston important?
The prepared medication should be used as directed to preserve proper drug stability and delivery characteristics.

66. What role does oxygen saturation monitoring play during respiratory assessment of a patient receiving Cayston?
It helps identify changes in oxygenation that may accompany worsening respiratory status or treatment intolerance.

67. What change in work of breathing could suggest that a patient is not tolerating inhaled aztreonam well?
An increase in work of breathing may suggest bronchospasm, airway irritation, or other respiratory deterioration.

68. Why should chest discomfort during Cayston administration be assessed rather than ignored?
Chest discomfort may accompany airway irritation, bronchospasm, or another adverse response that requires further evaluation.

69. Why is repeated nebulizer cleaning especially important in patients with cystic fibrosis?
Improperly cleaned equipment can become contaminated and potentially introduce additional microorganisms into already vulnerable airways.

70. What should patients be taught about sharing nebulizer equipment?
Nebulizer equipment should not be shared because this can increase the risk of transmitting respiratory pathogens.

71. Why are infection-control precautions particularly important among patients with cystic fibrosis?
Patients may carry organisms that can be transmitted to other individuals with cystic fibrosis and contribute to serious chronic infection.

72. What is one important difference between inhaled aztreonam and inhaled tobramycin?
Cayston is administered as 75 mg three times daily through the Altera system, while inhaled tobramycin uses different dosing and approved delivery systems.

73. Why should the response to long-term aztreonam therapy not be judged from a single nebulizer treatment?
Aztreonam is part of a chronic infection-management strategy, so effectiveness is assessed over time through symptoms, pulmonary function, cultures, and exacerbation patterns.

74. What clinical findings can be followed to evaluate the effectiveness of inhaled aztreonam therapy?
Respiratory symptoms, sputum production, breath sounds, oxygen saturation, FEV₁ trends, exacerbation frequency, and culture findings may be monitored.

75. What is the overall goal of inhaled aztreonam therapy in cystic fibrosis?
The goal is to help control chronic Pseudomonas aeruginosa pulmonary infection and improve respiratory symptoms as part of a broader cystic fibrosis treatment plan.

76. Why is aztreonam not classified as a bronchodilator?
Aztreonam does not relax bronchial smooth muscle; its primary action is antibacterial activity against susceptible gram-negative organisms.

77. Why is aztreonam not considered a mucolytic medication?
Aztreonam does not thin or break down respiratory secretions; it acts directly against susceptible bacteria.

78. What does colonization with Pseudomonas aeruginosa mean in the context of cystic fibrosis?
Colonization refers to the persistent presence of the organism in the respiratory tract, where it may contribute to chronic pulmonary disease.

79. Why can chronic Pseudomonas aeruginosa infection be difficult to eradicate in cystic fibrosis?
Abnormal airways and retained thick secretions can allow the organism to persist despite treatment.

80. What is the therapeutic purpose of achieving a high local concentration of aztreonam in the lungs?
A high local concentration increases antibiotic exposure at the site of pulmonary infection.

81. Why should clinicians avoid assuming that inhaled and intravenous aztreonam are interchangeable?
The two formulations are designed for different routes of administration and have different preparation and delivery requirements.

82. What is the significance of using a single-use vial for Cayston?
A single-use vial helps provide a measured dose and reduces the need to store or reuse an opened medication container.

83. What should a respiratory therapist verify before administering a prepared dose of Cayston?
The therapist should verify the correct medication, dose, reconstitution, delivery device, and treatment sequence.

84. Why is proper assembly of the Altera nebulizer important?
Incorrect assembly can interfere with aerosol generation and reduce the amount of medication delivered to the patient.

85. What can happen if the Altera nebulizer is not maintained properly?
Poor maintenance can impair device performance and may increase the risk of contamination.

86. Why may battery function be important when using the Altera nebulizer?
The electronic system requires an adequate power source to generate the aerosol correctly.

87. What is the relationship between airway caliber and aerosol deposition?
More open airways can improve penetration of aerosolized medication into the respiratory tract.

88. Why might severe airway obstruction reduce effective delivery of inhaled aztreonam?
Severe obstruction can limit airflow and prevent some aerosol particles from reaching more distal airways.

89. What is the purpose of comparing breath sounds before and after Cayston treatment?
The comparison can help identify new wheezing or other changes suggesting bronchospasm or airway irritation.

90. Why should respiratory rate be monitored during the first Cayston treatment?
An increasing respiratory rate may indicate worsening respiratory distress or intolerance to the medication.

91. Why should the patient’s subjective response be considered during aztreonam therapy?
Symptoms such as dyspnea, chest tightness, cough, or throat discomfort may provide early evidence of treatment intolerance.

92. What is one reason fever may be monitored in a patient receiving inhaled aztreonam?
Fever may be associated with the underlying respiratory infection or may occur as an adverse effect and should be evaluated in clinical context.

93. How does aztreonam differ from a bacteriostatic antibiotic?
Aztreonam kills susceptible bacteria, whereas a bacteriostatic drug primarily inhibits bacterial growth and reproduction.

94. Why are penicillin-binding proteins important targets for aztreonam?
They participate in bacterial cell-wall synthesis, so blocking them interferes with construction of a viable cell wall.

95. What happens to susceptible bacteria after aztreonam disrupts cell-wall synthesis?
Loss of normal cell-wall integrity ultimately results in bacterial death.

96. Why is antimicrobial stewardship especially important in patients who require repeated courses of inhaled antibiotics?
Repeated antibiotic exposure can select for resistant organisms, making future infections more difficult to treat.

97. What should be considered if a patient’s Pseudomonas aeruginosa isolate is resistant to aztreonam?
The treatment plan should be reassessed using culture and susceptibility information to identify a more appropriate antimicrobial option.

98. Why should respiratory culture results be reviewed over time in a patient with cystic fibrosis?
The organisms colonizing the airways and their susceptibility patterns can change during chronic disease and repeated antibiotic treatment.

99. What is the role of patient education in maintaining an effective 28-day Cayston treatment cycle?
Education helps the patient follow the prescribed dosing schedule, use the correct nebulizer, prepare doses properly, and recognize adverse effects.

100. What combination of factors is necessary for safe and effective inhaled aztreonam therapy?
Safe and effective therapy requires appropriate patient selection, confirmed or clinically relevant Pseudomonas aeruginosa infection, correct dosing and reconstitution, use of the Altera nebulizer, bronchodilator pretreatment, proper treatment sequencing, and monitoring for adverse reactions.

Final Thoughts

Aztreonam is a targeted inhaled antibiotic used primarily for managing Pseudomonas aeruginosa pulmonary infection in patients with cystic fibrosis. Cayston is administered as a 75 mg inhaled dose three times daily for 28 days, followed by 28 days without treatment, using the Altera Nebulizer System.

Safe administration requires bronchodilator pretreatment, appropriate sequencing with mucus-clearance therapies, correct nebulizer technique, and close monitoring for bronchospasm and allergic reactions.

Respiratory therapists should also consider pulmonary function, microbiological findings, antimicrobial resistance, equipment cleaning, and patient education when incorporating aztreonam into a comprehensive cystic fibrosis treatment plan.